Girma JP - Search Results

1

Thrombotic thrombocytopenic purpura associated with von Willebrand factor-cleaving protease (ADAMTS13) deficiency in children.

Loirat C, Veyradier A, Girma JP, Ribba AS, Meyer D. Loirat C, et al. Among authors: girma jp. Semin Thromb Hemost. 2006 Mar;32(2):90-7. doi: 10.1055/s-2006-939764. Semin Thromb Hemost. 2006. PMID: 16575683 Review.

2

Characterization of bitiscetin-2, a second form of bitiscetin from the venom of Bitis arietans : comparison of its binding site with the collagen-binding site on the von Willebrand factor A3-domain.

Obert B, Romijn RA, Houllier A, Huizinga EG, Girma JP. Obert B, et al. Among authors: girma jp. J Thromb Haemost. 2006 Jul;4(7):1596-601. doi: 10.1111/j.1538-7836.2006.01994.x. J Thromb Haemost. 2006. PMID: 16839359 Free article.

3

Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen.

Ribba AS, Loisel I, Lavergne JM, Juhan-Vague I, Obert B, Cherel G, Meyer D, Girma JP. Ribba AS, et al. Among authors: girma jp. Thromb Haemost. 2001 Sep;86(3):848-54. Thromb Haemost. 2001. PMID: 11583318

4

Functional analysis of the Arg91Gln substitution in the factor VIII binding domain of von Willebrand factor demonstrates variable phenotypic expression.

Lavergne JM, Piao Y, Ribba AS, Girma JP, Siguret V, Piétu G, Boyer-Neumann C, Schandelong A, Bahnak BR, Meyer D. Lavergne JM, et al. Among authors: girma jp. Thromb Haemost. 1993 Oct 18;70(4):691-6. Thromb Haemost. 1993. PMID: 8115998

5

A monoclonal antibody (B724) to von Willebrand factor recognizing an epitope within the A1 disulphide loop (Cys509-Cys695) discriminates between type 2A and type 2B von Willebrand disease.

Christophe O, Rouault C, Obert B, Piétu G, Meyer D, Girma JP. Christophe O, et al. Among authors: girma jp. Br J Haematol. 1995 May;90(1):195-203. doi: 10.1111/j.1365-2141.1995.tb03400.x. Br J Haematol. 1995. PMID: 7540413 Clinical Trial.

6

Selective inactivation of Von Willebrand factor binding to glycoprotein IIb/IIIa and to inhibitor monoclonal antibody 9 by site-directed mutagenesis.

Jumilly AL, Veyradier A, Ribba AS, Meyer D, Girma JP. Jumilly AL, et al. Among authors: girma jp. Hematol J. 2001;2(3):180-7. doi: 10.1038/sj.thj.6200093. Hematol J. 2001. PMID: 11920243

7

Mapping and functional studies of two alloantibodies developed in patients with type 3 von Willebrand disease.

Tout H, Obert B, Houllier A, Fressinaud E, Rothschild C, Meyer D, Girma JP. Tout H, et al. Among authors: girma jp. Thromb Haemost. 2000 Feb;83(2):274-81. Thromb Haemost. 2000. PMID: 10739386

8

Conformational changes in the A3 domain of von Willebrand factor modulate the interaction of the A1 domain with platelet glycoprotein Ib.

Obert B, Houllier A, Meyer D, Girma JP. Obert B, et al. Among authors: girma jp. Blood. 1999 Mar 15;93(6):1959-68. Blood. 1999. PMID: 10068669

9

Platelet aggregation induced by a monoclonal antibody to the A1 domain of von Willebrand factor.

Depraetere H, Ajzenberg N, Girma JP, Lacombe C, Meyer D, Deckmyn H, Baruch D. Depraetere H, et al. Among authors: girma jp. Blood. 1998 May 15;91(10):3792-9. Blood. 1998. PMID: 9573016

10

Structure-function relationship of the A1 domain of von Willebrand factor.

Girma JP, Ribba AS, Meyer D. Girma JP, et al. Thromb Haemost. 1995 Jul;74(1):156-60. Thromb Haemost. 1995. PMID: 8578449

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results